arrow
H

Hertzel C. Gerstein

mcmaster university
H指数:122
被引数:8.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Human leukocyte antigen genotype, body mass index status, and young-adult-onset type 1 diabetes

人类白细胞抗原基因型、体重指数状态及青年期发病的1型糖尿病

2026-08-310
OA
Polyendocrine Metabolic Ovarian Syndrome and the Entire Spectrum of Gestational Dysglycemia: A Population-Based Cohort Study

多内分泌代谢性卵巢综合征与妊娠期糖代谢异常的全谱:一项基于人群的队列研究

2026-08-280
OAAI
Rationale and design of a parallel randomised trial of a plant-based intensive lifestyle intervention for diabetes remission: The REmission of diabetes using a PlAnt-based weight loss InteRvention (REPAIR) trial

植物基强化生活方式干预促进糖尿病缓解的平行随机试验:REPAIR试验的原理与设计

2026-02-020
OAAI
Mendelian randomization study implicates inflammaging biomarkers in retinal vasculature; cardiovascular diseases; and longevity

孟德尔随机化研究将炎症衰老生物标志物与视网膜血管、心血管疾病以及长寿联系起来。

2025-10-240
PRE
Leveraging Co-Design, Design Thinking, and Service Blueprinting to Create Digital Health Behavior Change Innovations: Insights From a Co-Design Workshop With Type 2 Diabetes Remission Health Coaches

利用协同设计、设计思维和服务蓝图绘制来创建数字健康行为改变创新:来自与2型糖尿病缓解健康教练协同设计工作坊的见解

2025-04-290
PRE
Cardiometabolic risk factors and disease trends for atrial fibrillation in individuals with type 1 diabetes: a nationwide registry study

心房颤动的心血管代谢危险因素和疾病趋势:1型糖尿病人群的全国登记研究

2025-03-120
OA
Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity

比较胰高血糖素样肽1受体激动剂在亚洲与白种人群中心血管结局的疗效:系统评价和随机试验的Meta分析(研究对象为有或无2型糖尿病和/或超重或肥胖的人群)

2025-02-200
OA
Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis

GLP-1受体激动剂单独或联合SGLT2抑制剂治疗2型糖尿病的心血管、肾脏和安全性结局: 系统评价和荟萃分析

2024-11-261
OA
Great debate: pre-diabetes is not an evidence-based treatment target for cardiovascular risk reduction

大辩论: 糖尿病前期不是降低心血管风险的循证治疗目标

2024-10-100
PRE